Peer-review started: August 14, 2014
First decision: December 18, 2014
Revised: December 22, 2014
Accepted: December 29, 2014
Article in press: December 31, 2014
Published online: February 20, 2015
Processing time: 185 Days and 15.3 Hours
Melkersson-Rosenthal syndrome (MRS) is a rare, non-caseating granulomatous disorder of unknown etiology and undefined diagnostic criteria. The classical triad of recurrent orofacial edema, relapsing facial paralysis, and fissured tongue, is not frequently seen in its complete form, and many patients remain misdiagnosed or undiagnosed for years. The purpose of this study is to review the findings in the literature describing the Melkersson-Rosenthal syndrome with aim to identify its clinical and histopathological characteristics and correlate them with definitive diagnostic criteria and effective treatment modalities. A systematic review and analysis of more than 100 publications met eligibility criteria performed by the authors. Orofacial edema of unknown etiology is the most typical clinical feature of the Melkersson-Rosenthal syndrome. Its coexistence with of facial nerve palsy or fissured tongue could be characterized as an oligosymptomatic MRS. Many investigators suggest cheilitis granulomatosa as a monosymptomatic form of MRS, while patients with facial palsy and fissured tongue, without orofacial edema, should not be considered having MRS. Histological evidence is not necessary. Corticosteroids are generally accepted as the mainstay treatment.
Core tip: Orofacial edema of unknown etiology is the most typical clinical feature of the Melkersson-Rosenthal syndrome. Many investigators suggest cheilitis granulomatosa as a monosymptomatic form of melkersson-Rosenthal syndrome (MRS). The coexistence of orofacial edema with facial nerve palsy or fissured tongue could be characterized as an oligosymptomatic MRS. Patients with facial palsy and fissured tongue, without orofacial edema, should not be considered having MRS. Histological evidence is not necessary. Corticosteroids are generally accepted as the mainstay treatment.